A Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2018
At a glance
- Drugs R 107 Radikal Therapeutics (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Acronyms BEDROC-1
- Sponsors Douglas Pharmaceuticals
- 12 Nov 2018 Planned End Date changed from 10 Apr 2020 to 2 Oct 2020.
- 12 Nov 2018 Planned initiation date changed from 17 Sep 2018 to 19 Feb 2019.
- 28 Jun 2018 New trial record